Literature DB >> 17242922

Severe myalgia associated with mesalazine treatment in a child with Crohn's disease.

Mladen Persić1, Goran Palcevski, Irena Slavić, Vera Vlahović-Palcevski.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17242922     DOI: 10.1007/s00228-007-0260-1

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


× No keyword cloud information.
  5 in total

1.  Is an abbreviated Pediatric Crohn's Disease Activity Index better than the original?

Authors:  Melissa A Shepanski; Jonathan E Markowitz; Petar Mamula; Linda B Hurd; Robert N Baldassano
Journal:  J Pediatr Gastroenterol Nutr       Date:  2004-07       Impact factor: 2.839

Review 2.  Advances in therapeutic approaches to ulcerative colitis and Crohn's disease.

Authors:  Simon Travis
Journal:  Curr Gastroenterol Rep       Date:  2005-12

3.  Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines.

Authors:  R F Logan; T P van Staa
Journal:  Gut       Date:  2003-10       Impact factor: 23.059

4.  Evaluation of the pediatric crohn disease activity index: a prospective multicenter experience.

Authors:  Jeffrey Hyams; James Markowitz; Anthony Otley; Joel Rosh; David Mack; Athos Bousvaros; Subra Kugathasan; M Pfefferkorn; Vasundhara Tolia; Jonathan Evans; William Treem; Robert Wyllie; Robert Rothbaum; J del Rosario; Aubrey Katz; Adam Mezoff; M Oliva-Hemker; Trudy Lerer; Anne Griffiths
Journal:  J Pediatr Gastroenterol Nutr       Date:  2005-10       Impact factor: 2.839

5.  Interaction between azathioprine and aminosalicylates: an in vivo study in patients with Crohn's disease.

Authors:  O Dewit; R Vanheuverzwyn; J P Desager; Y Horsmans
Journal:  Aliment Pharmacol Ther       Date:  2002-01       Impact factor: 8.171

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.